Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
- Author:
Sun Min LIM
1
;
Sang-We KIM
;
Byoung Chul CHO
;
Jin Hyung KANG
;
Myung-Ju AHN
;
Dong-Wan KIM
;
Young-Chul KIM
;
Jin Soo LEE
;
Jong-Seok LEE
;
Sung Yong LEE
;
Keon Uk PARK
;
Ho Jung AN
;
Eun Kyung CHO
;
Tae Won JANG
;
Bong-Seog KIM
;
Joo-Hang KIM
;
Sung Sook LEE
;
Im-II NA
;
Seung Soo YOO
;
Ki Hyeong LEE
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2020;52(4):1112-1119
- CountryRepublic of Korea
- Language:0
-
Abstract:
Purpose:The introduction of immune checkpoint inhibitors represents a major advance in the treatment of lung cancer, allowing sustained recovery in a significant proportion of patients. Nivolumab is a monoclonal anti–programmed death cell protein 1 antibody licensed for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. In this study, we describe the demographic and clinical outcomes of patients with advanced NSCLC treated with nivolumab in the Korean expanded access program.
Materials and Methods:Previously treated patients with advanced non-squamous and squamous NSCLC patients received nivolumab at 3 mg/kg every 2 weeks up to 36 months. Efficacy data including investigator-assessed tumor response, progression data, survival, and safety data were collected.
Results:Two hundred ninety-nine patients were treated across 36 Korean centers. The objective response rate and disease control rate were 18% and 49%, respectively; the median progression-free survival was 2.1 months (95% confidence interval [CI], 1.87 to 3.45), and the overall survival (OS) was 13.2 months (95% CI, 10.6 to 18.9). Patients with smoking history and patients who experienced immune-related adverse events showed a prolonged OS. Cox regression analysis identified smoking history, presence of immune-related adverse events as positive factors associated with OS, while liver metastasis was a negative factor associated with OS. The safety profile was generally comparable to previously reported data.
Conclusion:This real-world analysis supports the use of nivolumab for pretreated NSCLC patients, including those with an older age.
